Search Results
Jul 13, 2026, 00:02 ET New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease
efficacy, safety and real-world patient and care partner experience data.Results showed that once-weekly 500 mg SC-AI achieved drug exposure similar to the approved IV initiation regimen (10 mg/kg every two weeks), supporting the expectation of similar clinical efficacy and safety, regardless of the route
More news about: BioArctic
Jul 12, 2026, 18:00 ET PMET Demonstrates >97% Caesium Extraction from Pollucite Concentrate
reported elements by ICP-AES. SGS program solids were analyzed for Cs and whole rock (Al, Fe, Mg, etc.) by XRF, S by LECO, and Rb and Ga on select samples by ICM-MS. Concentrate was analyzed for multi-element (59) by ICP-OES/MS.
More news about: PMET Resources Inc.
Jul 12, 2026, 11:15 ET LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026
safety and real-world patient and care partner experience findings. Results showed that once-weekly 500 mg SC-AI achieved drug exposure similar to the approved intravenous (IV) initiation regimen (10 mg/kg every two weeks), supporting the expectation of similar clinical efficacy and safety, independent
More news about: Eisai Inc.
Jul 10, 2026, 08:01 ET REIGN Total Body Fuel Signs QB Keelon Russell and RB Caden Durham to NIL Deals
their shared path, competitive edge, and rise through Division 1 college football.About REIGN Total Body FuelBlended with 300 mg of caffeine, 0 sugar, BCAAs, CoQ10 and electrolytes, REIGN TBF is designed for your active lifestyle. REIGN TBF is the ultimate fitness-focused beverage
More news about: REIGN Total Body Fuel
Jul 09, 2026, 17:22 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Erasca, Inc. of Class Action Lawsuit and Upcoming Deadlines - ERAS
after market hours on April 27, 2026, Erasca reported preliminary Phase 1 clinical data for ERAS-0015 and disclosing that one patient that received 24 mg of ERAS-0015 had died approximately a month after starting ERAS-0015. The patient was classified as a "Grade 3 TRAE of pneumonitis" that "progressed
More news about: Pomerantz LLP
Jul 09, 2026, 16:08 ET GORGIE Launches New Strategic Investor Campaign Featuring Alix Earle and Jon Bon Jovi
the category with better-for-you ingredients, functional benefits, and a community-driven approach where energy meets wellness. Each can features 150mg of green tea caffeine alongside wellness-supporting ingredients including Biotin, B Vitamins, and L-Theanine, delivering smooth, sustained energy without
More news about: GORGIE
Jul 09, 2026, 10:45 ET MISTRAS Group Recognized as a Star in MarketsandMarkets 360Quadrants for the NDT and Inspection Market
levels, evaluation of strategic collaborations, and other industry-relevant parameters.About MISTRAS GroupMISTRAS Group, Inc. (NYSE: MG) is a global leader in technology-enabled industrial asset integrity and laboratory testing solutions, serving critical strategic markets including oil
More news about: MarketsandMarkets
Jul 09, 2026, 10:31 ET Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight
interesting lupus asset after its Phase 2 SLEek study showed meaningful activity in moderate to severe systemic lupus erythematosus, with the 30 mg monotherapy arm meeting the primary endpoint and achieving steroid-sparing benefit versus placebo. Updated data presented in 2023 also showed durability
More news about: DelveInsight Business Research, LLP
Jul 09, 2026, 09:05 ET Upstate Elevator Launches Kanna and Kava Gummies, Its First Step Beyond Cannabinoids
Mango Brighter Mood Gummies: Featuring 10mg of premium kanna extract, 100mg of L-theanine, and vitamins B6 & B12, this uplifting formula is designed to support a positive mood, encourage balanced energy, and
More news about: Upstate Elevator
Jul 09, 2026, 08:31 ET MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity
safely achieve higher target doses and further optimize tolerability. In Part 3A, patients titrated from 16 mg to 48 mg, while in Part 3B, patients titrated from 16 mg to 32 mg and subsequently to 64 mg.
More news about: MetaVia Inc.
Jul 09, 2026, 08:05 ET FDA Approves ENNUMO™ (pegfilgrastim-pccg), Accord BioPharma's Second Pegfilgrastim Biosimilar to NEULASTA® (pegfilgrastim)
www.fda.gov/medwatch.ENNUMO (pegfilgrastim-pccg) injection for manual use is supplied in a 6 mg/0.6 mL single-dose prefilled syringe.Click here for
More news about: Accord BioPharma
Jul 09, 2026, 08:00 ET Astellas to Spotlight New Research for Geographic Atrophy at ASRS 2026 Annual Meeting
trials. These trials evaluated the safety and efficacy of monthly 2 mg intravitreal administration of IZERVAY in patients with GA secondary to AMD. For the first 12 months in both trials, patients were randomized to receive either IZERVAY 2 mg or sham monthly. There were 286 participants enrolled in GATHER1
More news about: Astellas Pharma Inc.
Jul 09, 2026, 06:05 ET ERAS DEADLINE NOTICE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
after market close on April 27, 2026, Erasca reported preliminary Phase I clinical data for ERAS-0015 and disclosed that one patient who received 24 mg of ERAS-0015 had died approximately one month after starting ERAS-0015. Erasca allegedly further disclosed that comparisons between ERAS-0015
More news about: Robbins Geller Rudman & Dowd LLP
Jul 09, 2026, 05:30 ET Foresee Pharmaceuticals Appoints Brian J. Groch as Chief Commercial Officer to Spearhead Commercial Launch of FP-001 42 mg for Central Precocious Puberty
affected children. The current standard of care involves treatment with GnRH agonists to halt pubertal progression.About FP-001 42 mgFP-001 42 mg is an investigational, sustained-release ready-to-use, subcutaneous formulation of leuprolide mesylate being developed for the treatment of
More news about: Foresee Pharmaceuticals Co., Ltd.
Jul 09, 2026, 05:28 ET InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation
patients with KRASG12C-mutation were enrolled in the single-arm phase II cohort and received ifebemtinib (100mg once a day) and garsorasib (600mg twice a day) orally. By data cutoff on September 16, 2025 reported in this paper, the median follow-up duration was 21.5 months. Ifebemtinib
More news about: InxMed Co., Ltd
Jul 08, 2026, 17:47 ET As FIFA World Cup Fever Sweeps North America, Soccer Players Need Rest
can be used both pre- and post-workout to alleviate muscle tension symptoms and spasms. Recommended dosage is two capsules daily, for a total of 22mg of CBD, and you should feel its effects within an hour.About Fusion CBD ProductsBased in Miami, Florida, Fusion CBD Products was
More news about: Fusion CBD Products
Jul 08, 2026, 09:02 ET UCB Awards Annual Myasthenia Gravis Scholarships to 15 Individuals Impacted by MG in the U.S.
myasthenia gravis community.Living with a rare disease like MG, or caring for someone who has MG, can present significant physical, emotional, and financial challenges. Through this scholarship program, UCB aims to empower people impacted by MG to continue their education, build new skills, and pursue
More news about: UCB
Jul 08, 2026, 09:00 ET Josh Allen and Natrol® Expand Partnership to Champion the Complete 24-Hour Wellness Cycle
cycle† and help users wake up feeling truly rested and refreshed†. It combines 5mg Melatonin, the #1 doctor-recommended supplement ingredient for sleep³ that helps users fall asleep faster and stay asleep longer†, with 100mg GABA, which promotes relaxation by signaling the brain to calm down†. The formula
More news about: Natrol
Jul 08, 2026, 08:00 ET Mighty Therapeutics Announces First Patient Dosed in Phase 4 Confirmatory Study of Elamipretide in Barth Syndrome
gasping syndrome) have occurred in preterm and low–birth weight neonates receiving benzyl alcohol (BA)-containing drugs.FORZINITY contains 20 mg BA/mL and is not approved for use in neonates or for IV administration.HypersensitivityReported reactions include rash, papular
More news about: Mighty Therapeutics
Jul 07, 2026, 11:00 ET The Springs Resort and Murrieta Hot Springs Resort Partner with CBD Brand, CauseMedic, for National Wellness Month
ritual, guests will receive a CauseMedic Wellness Shot, crafted with cold-pressed ginger, cayenne, ashwagandha, cordyceps, lion's mane, and 30 mg of full-spectrum CBD per shot. These invigorating beverages combine roots, fruits, and adaptogenic mushrooms in a flavorful daily wellness boost. The
More news about: The Springs Resort
Jul 07, 2026, 09:43 ET Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis
study in 71 patients with IPF across 22 sites in China. Patients were randomized to receive placebo, Rentosertib 30 mg once daily (QD), Rentosertib 30 mg twice daily (BID), or Rentosertib 60 mg QD for 12 weeks.The study met its primary safety and tolerability objective, with treatment-emergent adverse
More news about: Insilico Medicine
Jul 07, 2026, 08:30 ET cbdMD Sets a New Safety Standard for Broad Spectrum CBD With Self-Affirmed GRAS Determination
companies, today announced the completion of a self-affirmed Generally Recognized as Safe (GRAS) determination supporting the safe consumption of up to 200 mg per day of cannabidiol (CBD), as delivered in the Company's proprietary broad spectrum hemp extract, in healthy adults, addressing one of the most common
More news about: cbdMD, Inc.
Jul 06, 2026, 13:45 ET AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
FL (N=129) and FL (3-step step-up dose schedule N=86) after two or more lines of systemic therapy and included all the patients who enrolled to the 48 mg dose and received at least one dose of TEPKINLY. The most common adverse reactions (≥ 20%) were CRS, injection site reactions, fatigue, viral infection,
More news about: AbbVie
Jul 06, 2026, 13:45 ET AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
FL (N=129) and FL (3-step step-up dose schedule N=86) after two or more lines of systemic therapy and included all the patients who enrolled to the 48 mg dose and received at least one dose of TEPKINLY. The most common adverse reactions (≥ 20%) were CRS, injection site reactions, fatigue, viral infection,
More news about: AbbVie
Jul 06, 2026, 12:44 ET Someone Finally Made the "Zyn" for Cannabis! Meet KSHN Pouch Co.
a consistent 10mg of cannabis-derived THC, built perfectly for session dosing. Start with one for a light, functional lift, then build your buzz one pouch at a time until you hit your sweet spot. Because this method bypasses digestion entirely, 10mg in a pouch hits differently than 10mg in an edible.
More news about: KSHN Pouch Co